Liposomal Anticancer Drugs as Agents to be used in Combination with other Anticancer Agents: Studies on a Liposomal Formulation with two Encapsulated Drugs

References

• DeVita V.T., Jr., Hellman S., Rosenberg S.A. Cancer; Principles and Practice of Oncology, 3rd edition. J B Lippincott & Company, Philadelphia 1989
   Google Scholar
• Norton L. Conceptual basis for advances in the systemic drug therapy of breast. Cancer Semin Oncol 1997; 24: S11–212
   Google Scholar
• Ranson M.R., Carmichael J., O'Byrne K., Stewart S., Smith D., Howell A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997; 15: 3185–91
   PubMed Web of Science ®Google Scholar
• Muggia F.M., Hainsworth J.D., Jeffers S., Miller P., Groshen S., Tan M., Roman L., Uziely B., Muderspach L., Garcia A., Burnett A., Greco F.A., Morrow C.P., Paradiso L.J., Liang L.J. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987–93
   PubMed Web of Science ®Google Scholar
• Tulpule A., Yung R.C., Wernz J., Espina B.M., Myers A., Scadden D.T., Cabriales S., Haw M., Boswell W., Gill P.S. Phase II trial of liposomal dauno-rubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma. J Clin Oncol 1998; 16: 3369–74
   PubMed Web of Science ®Google Scholar
• Gill P.S., Espina B.M., Muggia F., Cabriales S., Tulpule A., Esplin J.A., Liebman H.A., Forssen E., Ross M.E., Levine A.M. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 1995; 13: 996–1003
   PubMed Web of Science ®Google Scholar
• Gelmon K.A., Tolcher A., Diab A.R., Bally M.B., Embree L., Hudon N., Dedhar C., Ayers D., Eisen A., Melosky B., Burge C., Logan P., Mayer L.D. Phase I study of liposomal vincristine. J Clin Oncol 1999; 17: 697–705
   PubMed Web of Science ®Google Scholar
• Batist G., Rao S.C., Ramakrishnan G., Gutheil J., Guthrie T., Welles L., Park Y. And the TLC D-99 Study Group. Phase III study of liposome-encapsulated doxorubicin (TLC D-99) versus doxorubicin (dox) in combination with cyclophosphamide (CPA) in patients (PTS.) with metastatic breast cancer (MBC). 35th Am Soc Clin Oncol, Abstr #486 1999, In press
   Google Scholar
• Mayer L.D., Reamer J., Bally M.B. Intravenous pretreatment with empty pH gradient liposomes alters the pharmacokinetics and toxicity of doxorubicin through in vivo active drug encapsulation. J Pharm Sci 1999; 88: 96–102
   PubMed Web of Science ®Google Scholar
• Lim H.J., Masin D., Madden T.D., Bally M.B. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. J Pharmacology & Exper Ther 1997; 281: 566–73
   PubMed Web of Science ®Google Scholar
• Boman N.L., Mayer L.D., Cullis P.R. Optimization of the retention properties of vincristine in liposomal systems. Biochim Biophys Acta 1993; 1152: 253–8
   PubMed Web of Science ®Google Scholar
• Webb M.S., Harasym T.O., Masin D., Bally M.B., Mayer L.D. Sphingo-myelin-cholesterol liposomes significantly enhance to pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 1995; 72: 896–904
   PubMed Web of Science ®Google Scholar
• Mayer L.D., Masin D., Bayar R., Boman N.L., Bally M.B. Pharmacology of liposomal vincristine in mice bearing LI210 ascitic and B16/BL6 solid tumours. Br J Cancer 1995; 71: 482–488
   PubMed Web of Science ®Google Scholar
• Webb M.S., Saxon D., Wong F.M.P., Lim H.S., Wang Z., Bally M.B., Chio L.S.L., Cullis P.R., Mayer L.D. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biochim Biophys Acta 1998; 1372: 272–82
   PubMed Web of Science ®Google Scholar
• Mayer L.D., Bally M.B., Loughrey H., Masin D., Cullis P.R. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res 1990; 50: 575–9
   PubMed Web of Science ®Google Scholar
• Webb M.S., Harasym T.O., Bally M.B., Mayer L.D. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 1995; 72: 896–904
   PubMed Web of Science ®Google Scholar
• Aviles A., Diaz-Maqueo J.C., Talavera A., Nambo M.J., Garcia E.L. Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy. Leukemia & Lymphoma 1994; 15: 153–7
   PubMed Web of Science ®Google Scholar
• Lipton J.H., Messner H.A., Curtis J.E., Atkins H.L., Minden M.D. Intensive remission induction therapy for chronic myeloid leukemia in blast phase with a goal of post-remission bone marrow transplant-a pilot study. Eur J Haematology 1996; 57: 42–45
   PubMedGoogle Scholar
• Zinzani P.L., Pavone E., Storti S., Moretti L., Fattori P.P., Guardigni L., Falini B., Gobbi M., Gentilini P., Lauta V.M., Bendandi Gherlinzoni M.F., Magagnoli M., Venturi S., Aitini E., Tabanelli M., Leone G., Liso V., Tura S. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkins lymphoma. Blood 1997; 89: 3974–3979
   PubMed Web of Science ®Google Scholar
• Hope M.J., Bally M.B., Webb G., Cullis P.R. Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta 1985; 812: 55–56
   PubMed Web of Science ®Google Scholar
• Olson F., Hunt C.A., Szoka F.C., Vail W.J., Papahadjopoulos D. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim Biophys Acta 1979; 557: 9–23
   PubMed Web of Science ®Google Scholar
• Pool G.L., French M.E., Edwards R.A., Huang L., Lumb R.H. Use of radiolabeled hexadecyl cholesteryl ether as a liposome marker. Lipids 1982; 17: 448–52
   PubMed Web of Science ®Google Scholar
• Mayer L.D., Hope M.J., Cullis P.R. Vesicles of variable sized produced by a rapid extrusion procedure. Biochim Biophys Acta 1986; 858: 161–8
   PubMed Web of Science ®Google Scholar
• Mayer L.D., Bally M.B., Hope M.J., Cullis P.R. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochim Biophys Acta 1985; 816: 294–302
   PubMed Web of Science ®Google Scholar
• Madden T.D., Harrigan P.R., Tai L.C.L., Bally M.B., Mayer L.D., Redelmeier T.E., Loughrey H.C., Tilcock C.P.S., Reinsih L.W., Cullis P.R. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: A survey. Chemistry & Physics of Lipids 1990; 53: 37–46
   PubMed Web of Science ®Google Scholar
• Redelmeier T.E., Mayer L.D., Wong K.F., Bally M.B., Cullis P.R. Proton flux in large unilamellar vesicles in response to membrane potentials and pH gradients. Biophys J 1989; 56: 385–393
   PubMed Web of Science ®Google Scholar
• Harrigan P.R., Hope M.J., Redelmeier T.E., Cullis P.R. Determination of transmembrane pH gradients and membrane potentials in liposomes. Biophys J 1992; 63: 1336–45
   PubMed Web of Science ®Google Scholar
• Chang C.W., Barber L., Ouyang C., Masin D., Bally M.B., Madden T.D. Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice. Br J Cancer 1997; 75: 169–77
   PubMed Web of Science ®Google Scholar
• Mui B.L.-S., Cullis P.R., Pritchard P.H., Madden T.D. Influence of plasma on the osmotic sensitivity of large unilamellar vesicles prepared by extrusion. J Biol Chem 1994; 269: 7364–70
   PubMedGoogle Scholar
• Monkkonen J., van Rooijen N., Ylitalo P. Effects of clodronate and pamidronate on splenic and hepatic phagocytic cells of mice. Pharmacol Toxicol 1991; 68: 284–6
   PubMedGoogle Scholar
• Longman S.A., Tardi P.G., Parr M.J., Chio L., Cullis P.R., Bally M.B. Accumulation of protein-coated liposomes in an extravascular site: influence of increasing carrier circulation lifetimes. J Pharmacol Exp Ther 1995; 275: 1177–84
   PubMed Web of Science ®Google Scholar
• Parr M.J. Circulation lifetimes and tumor accumulation of liposomal drug delivery systems. Ph.D. Thesis. University of British Columbia, Canada 1995
   Google Scholar
• Lasic D.D., Ceh B., Stuart M.C., Guo L., Frederik P.M., Barenholz Y. Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. Biochim Biophys Acta 1995; 1239: 145–56
   PubMed Web of Science ®Google Scholar